Drug Trial Radar · NCT07458347
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
545
Planned (sponsor's estimate)
Start
Apr 21, 2026
Primary completion
Apr 2028
Study completion Apr 2029
Sponsor
- Lead sponsor
- Kestrel Therapeutics, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC)
- KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
- KRAS-mutant Colorectal Cancer (CRC)
- Other KRAS-mutant Solid Tumors
Interventions
KST-6051Drug
KST-6051 will be administered orally as a tablet.
Gemcitabine/nab-paclitaxelDrug
Gemcitabine/nab-paclitaxel will be administered intravenously (IV).
CetuximabDrug
Cetuximab will be administered IV.
PembrolizumabDrug
Pembrolizumab will be administered IV.
mFOLFOX6Drug
mFOLFOX6 will be administered IV.
FOLFIRIDrug
FOLFIRI will be administered IV.
PemetrexedDrug
Pemetrexed will be administered IV.
CarboplatinDrug
Carboplatin will be administered IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days)Time frame: Up to Day 21 of Treatment Cycle 1
- Dose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2 years
- Dose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs)Time frame: Up to approximately 2 years
- Dose Expansion Cohorts: Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 2 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Mass General Brigham Cancer Institute at Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.